In vitro evidence that commercial influenza vaccines are not similar in their ability to activate human T cell responses
Center for Infectious Disease and Vaccine Research; Department of Biochemistry and Molecular Pharmacology
Immunology and Infectious Disease | Life Sciences | Medicine and Health Sciences
We evaluated three commercial trivalent inactivated vaccines (TIVs) from the 2007-2008 season in terms of their ability to elicit in vitro T cell responses. T cell-mediated immunity may offer a more cross-reactive vaccine approach for the prevention of pandemic or epidemic influenza. Human cytotoxic T cell lines demonstrated differences in matrix protein 1 and nucleocapsid protein recognition of autologous target cells. Peripheral blood mononuclear cells stimulated with each of the TIVs showed statistically significant differences between the vaccines in the numbers of IFNgamma producing cells activated. These data suggest that TIV vaccines are not similar in their ability to activate human T cell responses.
DOI of Published Version
Vaccine. 2009 Jan 7;27(2):319-27. Epub 2008 Oct 31. Link to article on publisher's site
Co MD, Orphin L, Cruz J, Pazoles PP, Green KM, Potts JA, Leporati AM, Babon JA, Evans JE, Ennis FA, Terajima M. (2009). In vitro evidence that commercial influenza vaccines are not similar in their ability to activate human T cell responses. GSBS Student Publications. https://doi.org/10.1016/j.vaccine.2008.09.092. Retrieved from https://escholarship.umassmed.edu/gsbs_sp/1613